Alogliptin (Vipidia®) is recommended as an option for restricted use for dual oral therapy within NHS Wales. Alogliptin (Vipidia®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control: • In combination with metformin (dual therapy), when metformin alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of a sulphonylurea is inappropriate; • In combination with a sulphonylurea (dual therapy), when a sulphonylurea alone, together with diet and exercise does not provide adequate glycaemic control in patients for whom the addition of metformin is inappropriate. Alogliptin (Vipidia®) is not recommended for use within NHS Wales outside of these circumstances.